Tagged with Healthcare

Baltics Marina Truhanova, deputy head of National Health Service Latvia, discusses the responsibility that the Latvian National Health System (NHS) has in terms of allocating their financial resources wisely, the importance of public procurement of medicines with the other two Baltic states to purchase cheaper drugs and allow for more access…

Brazil The Top 20 pharma companies in Brazil for 2017, combining the data for both the retail and non-retail markets. Sanofi leads the way, followed by local player NC Farma and Hypermarcas.

Brazil The Latin American pharmaceutical market in comparison. Brazil is by far the largest market. GDP real growth in Latin America regional comparison. Top 20 pharma companies in Latin America. Sanofi leads the way followed by Novartis and GSK. Brazil GDP and pharmaceutical market growth between 2014 and 2017. The evolution…

Canada Looking back on his first year as CEO of Organigram, Greg Engel proudly highlights the successful transition of the company from being a low-cost to a high-quality cannabis producer with premium products. He emphasizes Organigram’s close collaboration with both federal and provincial governments, on both the medical and recreational business,…

UK Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may present some solution to the problems the NHS is currently facing. In a career spanning over 30 years of service…

Lithuania Dr. Rasa Verkauskiene, a key opinion leader in endocrinology in Lithuania, discusses the levels of diabetes in the country and how various stakeholders are working together to combat what is a serious issue, affecting the lives of more than 120,000 Lithuanians. Could you please introduce yourself to our international audience?…

UK British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of facilitating accelerated access to medicines, and the potential fallout from Brexit to the UK’s life sciences ecosystem.   On the…

Latvia Svens Henkuzens, director of the State Agency of Medicines in Latvia discusses the key role of the organization in the country and the objectives he has set to further improve the access to innovative treatments for Latvian patients. Could you introduce the State Agency of Medicines and its mandate? “We…

Baltics Evija Buksa, general manager at Merck in Latvia, explains the strong history of Merck in the country as well as its key role in participating in the discussions to shape the Latvian healthcare system. Could you please start by introducing Merck in Latvia and the strategic significance of the local…

Ecuador Juan Carlos Galarza, executive director of Ecuador’s National Health Regulation, Control and Surveillance Agency (ARCSA), discusses the multiple procedural improvements that the Agency has recently implemented with the objective of increasing its international recognition, the benefits of these actions for Ecuadorians – who will have faster and safer access to…

UK Much of the new inward investment in the UK from international pharmaceutical companies is from those that wish their discovery science to be in close adjacency to the most successful basic science programmes in biomedicinein the world. The co-location of pharmaceutical discovery sciences adjacent to the best universities (AstraZeneca in Cambridge, Novo Nordisk…

UK Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on the UK life sciences landscape.   One of the key matters for us is that we don’t have direct customers.…